VHOSPITAL.CLINIC · Antiparasitic Treatment
Ivermectin 200 μg/kg/day for 2 days is the first-line treatment for strongyloidiasis, achieving cure rates of 95–100% — superior to albendazole's 50–80%.
Ivermectin binds glutamate-gated chloride channels (GluCl) in Strongyloides stercoralis, causing neuronal hyperpolarisation, paralysis of the worm's pharynx and body wall, and death — acting on both intestinal and skin-migrating larvae.
Standard: 200 μg/kg once daily for 2 days. Hyperinfection: 200 μg/kg daily until negative stool cultures for 2 weeks. Take on empty stomach. Repeat treatment at 2 weeks if follow-up stool is positive.
This is a general reference. Always follow your physician's prescription and current treatment guidelines.
Ivermectin achieves cure rates of 95–100% for strongyloidiasis vs 50–80% for albendazole. Ivermectin targets both stages of the parasite more effectively. WHO guidelines list ivermectin as the drug of choice.
In immunocompromised patients, Strongyloides autoinfection can become hyperinfection — massively amplified larval migration causing pneumonitis, meningitis, and gram-negative sepsis as larvae carry gut bacteria through the intestinal wall. Mortality is high without prompt treatment.
Follow-up stool microscopy and Strongyloides serology at 3 and 6 months post-treatment. Serology titres should decline. For immunocompromised patients, more frequent follow-up is needed due to higher recurrence risk.
By treating Strongyloidiasis, Ivermectin addresses these associated symptoms:
Explore treatment protocols, drug comparisons, resistance patterns, and prevention strategies for all parasitic diseases.
Get a structured AI clinical assessment based on your symptoms — possible parasitic causes, red flags, and recommended next steps.
Start Free AI Analysis →Content on this page is informed by evidence-based clinical sources including: